An Open-label Long-term Safety Study of Buntanetap in Participants With AD
← catalyst calendarNCT07757204 · readout in 1,282 d
Sponsored by Annovis Bio Inc. (industry) · ANVS — their whole pipeline →.
Phase
Phase 2/3
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
400estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-21 | estimated | When the study began enrolling |
| Primary completion | 2030-02-21 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alzheimer's Dementia (AD)
Intervention
- Drug: buntanetap/posiphen
Primary outcomes
what the primary-completion date above is the date OFSafety of buntanetap
measured 24 months of treatment
Adverse Events (AE)
measured 24 months of study
Treatment Emergent Adverse Events (TEAE)
measured 24 months of study
Serious Adverse Events (SAE)
measured 24 months of study
Permalink · ANVS's whole pipeline · Catalyst calendar · Every registered study · What changed